Compare Coursera Inc (COUR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Sana Biotechnology Inc — how do they compare? Coursera Inc trades at $5.65 (market cap $1.50B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Coursera Inc is the larger of the two by market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| COUR | SANA | |
|---|---|---|
Market Cap | $1.50B | $1.13B |
Sector | Consumer Staples | Health |
52-Week High | $12.20 | $5.92 |
52-Week Low | $5.09 | $2.68 |
Enterprise Value | $759.54M | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.575, down 3.21% today, with a bearish technical signal and mixed earnings performance. Revenue growth continues with 2025 reaching $757.5M, though the company remains unprofitable with a -15.39% net margin. Recent Q2 2026 earnings beat expectations at $0.17 per share versus $0.10 expected. Analyst sentiment is positive with 53% buy ratings and a $7.70 consensus price target representing 38% upside potential.
The stock offers growth exposure to online education but faces profitability challenges. Upside catalysts include continued revenue expansion and strategic AI investments, while risks include persistent losses and competitive pressures. Wall Street sees significant undervaluation despite near-term headwinds.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
